In the perioperative chemotherapy group, 151 (83%) patients were resected after a median of six (range 1–6) preoperative cycles and 115 (63%) patients received a median six (1–8) postoperative cycles. 152 (84%) patients were resected in the surgery group. The absolute increase in rate of progression-free survival at 3 years was 7·3%(from 28·1%[95·66%CI 21·3–35·5] to 35·4%[28·1–42·7]; HR 0·79 [0·62–1·02]; p=0·058) in randomised patients; 8·1%(from 28·1%[21·2–36·6] to 36·2%[28·7–43·8]; HR 0·77 [0·60–1·00]; p=0·041) in eligible patients; and 9·2%(from 33·2%[25·3–41·2] to 42·4%[34·0–50·5]; HR 0·73 [0·55–0·97]; p=0·025) in patients undergoing resection. 139 patients died (64 in perioperative chemotherapy group vs 75 in surgery group). Reversible postoperative complications occurred more often after chemotherapy than after surgery (40/159 [25%] vs 27/170 [16%]; p=0·04). After surgery we recorded two deaths in the surgery alone group and one in the perioperative chemotherapy group.
Perioperative chemotherapy with FOLFOX4 is compatible with major liver surgery and reduces the risk of events of progression-free survival in eligible and resected patients.
Swedish Cancer Society, Cancer Research UK, Ligue Nationale Contre le Cancer, US National Cancer Institute, Sanofi-Aventis.
PDF (169 K) [Sponsored Article]  text of this document" title="You are not entitled to access the full text of this document" width=12 height=14"> te=12%2F31%2F2001&_rdoc=1&_fmt=high&_orig=article&_cdi=5024&_sort=v&_docanchor=&view=c&_ct=4337&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=111c66af9f039713c4793e4584b45fc9">Improved survival after one course of perioperative chemotherapy in early breast cancer patients: longEuropean Journal of Cancer, Volume 37, Issue 17, 2001, Pages 2184-2193 J. A. van der Hage, C. J. H. van de Velde, J. -P. Julien, J. -L. Floiras, T. Delozier, C. Vandervelden, L. Duchateau, cooperating investigators Abstract The aim of this study was to examine whether one course of perioperative polychemotherapy yields better results in terms of survival, progression-free survival (PFS) and locoregional control than surgery alone in early stage breast cancer. From 1986 to 1991, 2795 patients with stage I/II breast cancer were randomised to receive either one perioperative course of an anthracycline-containing chemotherapeutic regimen within 36 h after surgery or surgery alone. Patients were followed-up for overall survival, PFS and locoregional recurrence. The median follow-up period at time of the analysis was 11 years. PFS and locoregional control were significantly better (P=0.025 and P=0.004, respectively) in the perioperative chemotherapy arm. Node-negative patients seemed to benefit most from the perioperative FAC. Patients who received perioperative chemotherapy and locoregional therapy alone had significantly better overall survival rates than patients who received locoregional therapy alone (P=0.004). Patients who received additional systemic therapy did not seem to benefit from one course of perioperative chemotherapy (P=0.65). One course of perioperative polychemotherapy does improve PFS and locoregional control in early stage breast cancers. This effect is still present after 11 years of follow-up. te=12%2F31%2F2001&_sk=999629982&view=c&wchp=dGLbVzz-zSkWz&md5=02203b3fa91345566d5aeb8989decb07&ie=/sdarticle.pdf"> Purchase PDF (174 K) |
| text of this document" title="You are not entitled to access the full text of this document" width=12 height=14"> te=09%2F30%2F2007&_rdoc=1&_fmt=high&_orig=article&_cdi=5101&_sort=v&_docanchor=&view=c&_ct=4337&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=f7d78872b738bb5980afd5f88ef23632">Cost Journal of the American College of Surgeons, Volume 205, Issue 3, Supplement 1, September 2007, Pages S70-S71 Shelly T. Karuna, Richard Thirlby, Thomas Biehl te=09%2F30%2F2007&_sk=997949996.8998&view=c&wchp=dGLbVzz-zSkWz&md5=16f64eb0f36e61b86d8650e6a3b1b8bd&ie=/sdarticle.pdf"> Purchase PDF (46 K) |
 | tedArtURL&_udi=B6T1B-4S3HTTC-5&_orig=article&_acct=C000050221&_version=1&_userid=10&md5=ab01adb7d1aa7d120f3072ce1fb85e70">View More Related Articles |
| View Record in Scopus |
doi:10.1016/S0140-6736(08)60429-8 
te or Link Using DOI (Opens New Window)" title="How to Cite or Link Using DOI (Opens New Window)" border="0" align="absmiddle"> Perioperative chemotherapy for resectable hepatic metastases
